White lung

Chrysalis Receives FDA Approval to Initiate Clinical Trials with Chrysalin™ (TP508)

Retrieved on: 
Tuesday, September 26, 2023
Research, FDA, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Science, Acute respiratory distress syndrome, Tissue, Pupa, US Foods, Radiation, Biomedical Advanced Research and Development Authority, Bone fracture, University, Office of Inspector General, U.S. Department of Health and Human Services, Human services, Safety, National Institute of Allergy and Infectious Diseases, Infection, Brain, COVID, Inflammation, Lung, Pulmonary fibrosis, UTMB, Fibrosis, Development, Ischemia, Patient, Diagnosis, Chronic radiation syndrome, Carney, NIAID, Trauma, UTHealth School of Dentistry, BARDA, IND, Food, White lung, Pharmaceutical industry

Chrysalis BioTherapeutics, Inc. announced today that the US Food and Drug Administration (FDA) has given the company permission to initiate human clinical trials aimed at treating acute lung failure.

Key Points: 
  • Chrysalis BioTherapeutics, Inc. announced today that the US Food and Drug Administration (FDA) has given the company permission to initiate human clinical trials aimed at treating acute lung failure.
  • Other animal studies show potential TP508 benefit in treating acute lung injury, chronic smoke inhalation, and mitigating radiation effects on brain and other tissues.
  • “TP508 is a natural regenerative peptide that accelerates tissue repair and revascularization while modulating the inflammatory response.
  • Chrysalis is using UTMB, Houston-area, and national advisors to advance TP508 for treating pulmonary indications.

ReAlta Life Sciences Announces Poster Presentation at the European Respiratory Society 2023 International Congress

Retrieved on: 
Tuesday, September 5, 2023
Research, Infectious Diseases, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, European Respiratory Society, Human, Protocol, Reactive airway disease, Toxicology, Hypoxia (medical), Medical research, Immune system, Fraunhofer Society, Rare, International Congress on Tuberculosis, POM, White lung, Pharmaceutical industry

ReAlta Life Sciences (“ReAlta”), Inc., a clinical-stage biotech company addressing life-threatening rare diseases through harnessing the power of the immune system, today announced that it will be presenting additional clinical data from its Phase 1b trial in healthy volunteers on RLS-0071 at the European Respiratory Society 2023 International Congress taking place in Milan, Italy on 9-13 September, 2023.

Key Points: 
  • ReAlta Life Sciences (“ReAlta”), Inc., a clinical-stage biotech company addressing life-threatening rare diseases through harnessing the power of the immune system, today announced that it will be presenting additional clinical data from its Phase 1b trial in healthy volunteers on RLS-0071 at the European Respiratory Society 2023 International Congress taking place in Milan, Italy on 9-13 September, 2023.
  • RLS-0071, the Company’s complement inhibitor and innate anti-inflammatory product candidate, is being developed as a treatment for hypoxic ischemic encephalopathy and other acute inflammatory and rare diseases.
  • The new data will be presented by Prof. Dr. Jens M. Hohlfeld, Division Director of Airway Research at the Fraunhofer Institute for Toxicology and Experimental Medicine (Hannover, Germany) and lead investigator on the Phase 1b trial.
  • Session 68 (PA608) – From bench to bedside: translational studies in airway diseases

The Inner Circle Acknowledges, Josel Doyle as a Pinnacle Platinum Healthcare Professional for her contributions to the field of Neonatology

Retrieved on: 
Monday, August 21, 2023
Hospice and palliative medicine, Neonatal withdrawal, St. George's University School of Medicine, Education, NAS, Pediatrics, Parent, Infection, Pediatrics (journal), American Academy, Multimedia, Inner circle, NYU Langone Hospital – Long Island, White lung, Sleep-related breathing disorder, Patient, Love, Nuclear, Stony Brook University Hospital, Birth, Interior design, Nursing, Medicine, Neonatology

TOPEKA, Kan., Aug. 21, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Josel Doyle is acknowledged as a Pinnacle Platinum Healthcare Professional for her contributions to the field of Neonatology.

Key Points: 
  • TOPEKA, Kan., Aug. 21, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Josel Doyle is acknowledged as a Pinnacle Platinum Healthcare Professional for her contributions to the field of Neonatology.
  • Dr. Doyle pursued higher education at St. Georges University School of Medicine where she earned an undergraduate and medical degrees.
  • She completed a residency in pediatrics and a fellowship in neonatal-perinatal medicine at Winthrop University Hospital.
  • Recognized for her leadership early in her career, she also served as Chief Resident at Stony Brook University Hospital.

BioCardia Reports Second Quarter 2023 Business Highlights and Financial Results

Retrieved on: 
Wednesday, August 9, 2023
BCDA, DSMB, Survival, Stem cell, Data monitoring committee, Protein, Data analysis, Patent, Patient, Update, Heart, Maintenance, Therapy, Heart failure, Culture, Consultant, Facial muscles, MSC, Japan Patent Office, Security (finance), Phase, FDA, IND, Safety, Opposition procedure before the European Patent Office, Pharmaceuticals and Medical Devices Agency, Cell, IRB, PMDA, White lung, FS, Research, Breakthrough, Quality of life, Data collection, COVID, Microsoft Exchange Server, Trial of the century, MRI, European Patent Convention, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Gene, Food, Pharmaceutical industry, Medical device, Cryptocurrency, Helix, NYHA

SUNNYVALE, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reports financial results for the second quarter of 2023 and filed its quarterly report on Form 10-Q for the three and six months ended June 30, 2023 with the Securities and Exchange Commission.

Key Points: 
  • SUNNYVALE, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reports financial results for the second quarter of 2023 and filed its quarterly report on Form 10-Q for the three and six months ended June 30, 2023 with the Securities and Exchange Commission.
  • The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights.
  • On July 12, 2023, the planned Data Safety Monitoring Board (DSMB) meeting was held utilizing the adaptive statistical analysis plan reviewed by FDA in the second quarter.
  • Second Quarter 2023 Financial Results:
    Revenues were approximately $43,000 for the three months ended June 2023, compared to approximately $974,000 in the three months ended June 2022, due primarily to the timing of collaboration agreement revenues.

Feinstein Institutes Researchers Discover Defensive Molecules That Can Worsen Inflammation in Sepsis

Retrieved on: 
Friday, July 21, 2023
Research, Science, Infection, Medicine, Neutrophil, Macrophage, Journal, Survival, Feinstein Institutes for Medical Research, Apan Jewellers, DRS, Multimedia, Inflammation, Cell, Doctor of Philosophy, Spleen, Patient, MD, Blood, Immune system, DSM-IV codes, APAN, Paper, Bacteria, Credit, Death, Immunosuppression, Radiation exposure, National Institutes of Health Clinical Center, White lung, Pharmaceutical industry, Medical device, Vaccine, Sepsis

In a potential therapeutic breakthrough, investigators at The Feinstein Institutes for Medical Research have identified a type of white blood cell that can worsen inflammation in sepsis and opens up new avenues of research to treat the deadly condition.

Key Points: 
  • In a potential therapeutic breakthrough, investigators at The Feinstein Institutes for Medical Research have identified a type of white blood cell that can worsen inflammation in sepsis and opens up new avenues of research to treat the deadly condition.
  • (Credit: Feinstein Institutes)
    Results of the study, led by Ping Wang, MD , professor and chief scientific officer at the Feinstein Institutes, were published today in the Journal of Clinical Investigation .
  • “APANs, when triggered, can result in devastating circumstances for patients who have sepsis,” said Dr. Wang, senior author of the paper.
  • Last year, Dr. Wang and co-principal investigators at the Feinstein Institutes received $3.8 million from the National Institute of Health to study sepsis and radiation exposure.

Global Acute Respiratory Distress Syndrome Market Report 2023-2028: Industry Trends, Growth, Impact of Inflation, Opportunities, Company Analysis - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 7, 2023
Pharmaceutical, Health, Medical Devices, Research and development, Failure, Bed, Hospital, COVID-19, Ageing, Risk, Lung, Government, Incidence, Chronic Respiratory Disease, Patient, Transfusion-related acute lung injury, Developed country, Viral, Acute respiratory distress syndrome, ICU, R, Air pollution, Diagnosis, White lung, Dietary supplement, Pharmaceutical industry, Medical device, Nursing, Growth

The "Acute Respiratory Distress Syndrome Market, Global Forecast 2023-2028, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Acute Respiratory Distress Syndrome Market, Global Forecast 2023-2028, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • The other factors forecasted to propel the development of the worldwide acute respiratory distress syndrome (ARDS) market include the rising rate of air pollution and lifestyle-related diseases and Increasing accident rates and trauma-causing ARDS market.
  • However, the high cost of devices, lack of awareness about diseases, failure of trials for ARDS, and stringent regulation for approvals are the main factors restraining the global acute respiratory distress syndrome market.
  • In addition, nebulization devices dominate the acute respiratory distress syndrome market due to their low cost and wide availability.

Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference

Retrieved on: 
Wednesday, May 24, 2023
COL1A1, Mahru, Therapy, ITGB6, Serum, ATS, VIM, Vanderbilt University Medical Center, FVC, Biomarker, Fibroblast, American Thoracic Society, QLF, White lung, Fibrosis, Vital capacity, International Conference on Afghanistan, London (2010), HIV disease progression rates, SAN, IPF, Death, Gene, Conference, Idiopathic pulmonary fibrosis, Pharmaceutical industry, Vaccine, Medicine

“Data presented at this year’s ATS conference highlight some of the strong foundational work conducted and encouraging interim clinical results from our Phase 2a INTEGRIS-IPF trial that warrant the progression of bexotegrast into late-stage clinical development,” said Éric Lefebvre, M.D., Chief Medical Officer at Pliant Therapeutics.

Key Points: 
  • “Data presented at this year’s ATS conference highlight some of the strong foundational work conducted and encouraging interim clinical results from our Phase 2a INTEGRIS-IPF trial that warrant the progression of bexotegrast into late-stage clinical development,” said Éric Lefebvre, M.D., Chief Medical Officer at Pliant Therapeutics.
  • In an oral presentation, Lisa H. Lancaster, M.D., Professor of Medicine at Vanderbilt University Medical Center and principal investigator of the INTEGRIS-IPF Phase 2a trial, reviewed 12-week data from the trial.
  • Results from a differential gene expression analysis suggest the mechanism of action of bexotegrast may be both independent of, and complementary to, that of currently approved therapies.
  • Results also demonstrated the utility of combining single cell transcriptomic techniques with fibrotic human tissue to evaluate the mechanism of action of novel anti-fibrotic therapies, such as bexotegrast.

ReAlta Life Sciences Announces Poster Presentation at the American Thoracic Society 2023 Annual Meeting

Retrieved on: 
Thursday, March 30, 2023
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Human, Protocol, Toxicology, American Thoracic Society, Hypoxia (medical), Medical research, Immune system, Annual general meeting, Fraunhofer Society, POM, White lung, Pharmaceutical industry

ReAlta Life Sciences (“ReAlta”), Inc., a company addressing life-threatening rare diseases through harnessing the power of the immune system, today announced that it will be presenting clinical data from its Phase 1b trial in healthy volunteers on RLS-0071 at the American Thoracic Society 2023 Annual Meeting taking place in Washington, DC on May 19-24, 2023.

Key Points: 
  • ReAlta Life Sciences (“ReAlta”), Inc., a company addressing life-threatening rare diseases through harnessing the power of the immune system, today announced that it will be presenting clinical data from its Phase 1b trial in healthy volunteers on RLS-0071 at the American Thoracic Society 2023 Annual Meeting taking place in Washington, DC on May 19-24, 2023.
  • RLS-0071, the Company’s complement inhibitor and innate anti-inflammatory product candidate, is being developed as a treatment for hypoxic ischemic encephalopathy and other rare diseases.
  • The data will be presented by Prof. Dr. Jens M. Hohlfeld, Division Director of Airway Research at the Fraunhofer Institute for Toxicology and Experimental Medicine in Germany, and lead investigator on the Phase 1b trial.
  • RLS-0071, A Novel Dual-targeting Anti-inflammatory Agent, Demonstrates Proof of Mechanism in a Phase 1b Inhaled LPS Study Significantly Reducing Lung Neutrophils

CalciMedica Announces Closing of Merger with Graybug Vision and Concurrent Private Placement

Retrieved on: 
Monday, March 20, 2023
LLP, Doctor of Pharmacy, ALL, Acute lymphoblastic leukemia, ALI, CRAC, Pancreas, AP, Toxicity, AAP, AKI, Lung, Development, Acute kidney injury, Cooley LLP, Patient, Acute pancreatitis, Systemic inflammatory response syndrome, Kidney, Acute respiratory distress syndrome, Oppenheimer, Asparaginase, Research, White lung, SIRS, Pharmaceutical industry, Security (finance)

LA JOLLA, Calif., March 20, 2023 (GLOBE NEWSWIRE) -- CalciMedica Inc. (CalciMedica) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need, today announced the closing of its previously announced merger with Graybug Vision, Inc. CalciMedica’s stock will commence trading on March 21, 2023 on the Nasdaq Global Market under the trading symbol “CALC”.

Key Points: 
  • Immediately prior to the closing of the merger, CalciMedica completed the previously announced private placement of $10.3 million.
  • “With the closing of this merger, CalciMedica enters into a pivotal new phase of its future development, and we are extremely thankful to have partnered with Graybug for this transformational deal,” said Rachel Leheny, Ph.D., Chief Executive Officer of CalciMedica.
  • Immediately following the merger, CalciMedica had approximately 5.5 million shares of common stock outstanding.
  • In connection with the merger, the parties waived the condition that the shares of Graybug Vision, Inc. common stock to be issued to CalciMedica stockholders in the merger be approved for listing on Nasdaq as of the closing of the merger.

MediciNova Announces Additional Extension of BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury

Retrieved on: 
Thursday, March 9, 2023
Code, MCM, Mothers (Tokyo Stock Exchange), Biomedical Advanced Research and Development Authority, Tokyo Stock Exchange, Development, Administration, Acute respiratory distress syndrome, ASPR, BARDA, Human services, White lung, Chlorine, United States Department of Health and Human Services, ALI, Rare-earth element, Medical device

LA JOLLA, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced a modification to its contract with the Biomedical Advanced Research and Development Authority (BARDA), a part of the Administration for Strategic Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services, to repurpose MN-166 (ibudilast) as a potential medical countermeasure (MCM) against chlorine gas-induced lung damage such as acute respiratory distress syndrome (ARDS) and acute lung injury (ALI).

Key Points: 
  • LA JOLLA, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced a modification to its contract with the Biomedical Advanced Research and Development Authority (BARDA), a part of the Administration for Strategic Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services, to repurpose MN-166 (ibudilast) as a potential medical countermeasure (MCM) against chlorine gas-induced lung damage such as acute respiratory distress syndrome (ARDS) and acute lung injury (ALI).
  • The contract was amended to extend the period of performance until May 31, 2023.
  • This project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority, under contract number 75A50121C00022.